DNAtrix, Inc.
United States
28 articles about DNAtrix, Inc.
-
Merck & Co. And DNAtrix, Inc. Announce Phase II Immuno-Oncology Collaboration In Patients With Aggressive Form Of Brain Cancer
10/1/2015
-
DNAtrix, Inc. Collaborators Present Data On A Novel Oncolytic Adenovirus Expressing OX40 Ligand That Promotes Antitumor Immunity
6/16/2015
-
Alcyone Lifesciences And DNAtrix, Inc. Enter Clinical Collaboration For Brain Cancer
5/19/2015
-
DNAtrix, Inc. Completes $20 Million Series B Financing
10/14/2014
-
FDA Grants Orphan Drug Designation To DNAtrix, Inc.'s DNX-2401 For The Treatment Of Malignant Glioma
10/7/2014
-
DNAtrix, Inc. Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial
9/16/2014
-
FDA Release: DNAtrix, Inc. Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma
6/17/2014
-
DNAtrix, Inc. Awarded $10.8 Million Grant By The Cancer Prevention And Research Institute Of Texas
2/24/2014